Literature DB >> 9147411

The in vitro formation of recombinant tau polymers: effect of phosphorylation and glycation.

M D Ledesma1, M Medina, J Avila.   

Abstract

Tau Isolated from paired helical filaments, aberrant structures that appear in Alzheimer disease (AD) patients' brains, show at least two posttranslational modifications: phosphorylation (Grundke-Iqbal et al., 1986; Ihara et al., 1986) and glycation (Ledesma et al., 1994; Yan et al., 1994). To test whether these modifications could affect the capacity of tau to self-aggregate, recombinant tau was phosphorylated and glycated, and its capacity to form polymers analyzed. Our results indicate that on phosphorylation and glycation, the capacity of tau to form aggregates increases, and that glycation of tau could stabilize the assembled polymers and could facilitate formation of bundles from these polymers.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9147411     DOI: 10.1007/bf02815107

Source DB:  PubMed          Journal:  Mol Chem Neuropathol        ISSN: 1044-7393


  12 in total

1.  NMNAT suppresses tau-induced neurodegeneration by promoting clearance of hyperphosphorylated tau oligomers in a Drosophila model of tauopathy.

Authors:  Yousuf O Ali; Kai Ruan; R Grace Zhai
Journal:  Hum Mol Genet       Date:  2011-09-30       Impact factor: 6.150

Review 2.  Cellular factors modulating the mechanism of tau protein aggregation.

Authors:  Sarah N Fontaine; Jonathan J Sabbagh; Jeremy Baker; Carlos R Martinez-Licha; April Darling; Chad A Dickey
Journal:  Cell Mol Life Sci       Date:  2015-02-11       Impact factor: 9.261

Review 3.  Molecular imaging of Alzheimer disease pathology.

Authors:  K Kantarci
Journal:  AJNR Am J Neuroradiol       Date:  2014-02-06       Impact factor: 3.825

4.  APOE modifies the association between Aβ load and cognition in cognitively normal older adults.

Authors:  K Kantarci; V Lowe; S A Przybelski; S D Weigand; M L Senjem; R J Ivnik; G M Preboske; R Roberts; Y E Geda; B F Boeve; D S Knopman; R C Petersen; C R Jack
Journal:  Neurology       Date:  2011-12-21       Impact factor: 9.910

5.  Role for glyoxalase I in Alzheimer's disease.

Authors:  Feng Chen; M Axel Wollmer; Frederic Hoerndli; Gerald Münch; Björn Kuhla; Evgeny I Rogaev; Magdalini Tsolaki; Andreas Papassotiropoulos; Jürgen Götz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-05       Impact factor: 11.205

Review 6.  Insight of brain degenerative protein modifications in the pathology of neurodegeneration and dementia by proteomic profiling.

Authors:  Sunil S Adav; Siu Kwan Sze
Journal:  Mol Brain       Date:  2016-11-03       Impact factor: 4.041

7.  Targeting gonadotropins: an alternative option for Alzheimer disease treatment.

Authors:  Gemma Casadesus; Emma Ramiro Puig; Kate M Webber; Craig S Atwood; Margarida Castell Escuer; Richard L Bowen; George Perry; Mark A Smith
Journal:  J Biomed Biotechnol       Date:  2006

Review 8.  Lysine-Directed Post-translational Modifications of Tau Protein in Alzheimer's Disease and Related Tauopathies.

Authors:  Christiana Kontaxi; Pedro Piccardo; Andrew C Gill
Journal:  Front Mol Biosci       Date:  2017-08-11

Review 9.  Use of okadaic acid to identify relevant phosphoepitopes in pathology: a focus on neurodegeneration.

Authors:  Miguel Medina; Jesús Avila; Nieves Villanueva
Journal:  Mar Drugs       Date:  2013-05-21       Impact factor: 5.118

Review 10.  Tau protein modifications and interactions: their role in function and dysfunction.

Authors:  Anna Mietelska-Porowska; Urszula Wasik; Marcelina Goras; Anna Filipek; Grazyna Niewiadomska
Journal:  Int J Mol Sci       Date:  2014-03-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.